Precision therapy for a subgroup of genetically defined metastatic castration-resistant
prostate cancer patients may become a reality in the near future. DNA damage repair
gene mutated prostate cancer might be vulnerable to treatment with PARP inhibitors
(PARPi). PARPi clinical trials for prostate cancer investigate both germline and somatic
genomic alterations of 43 genes for the applicability as genomic biomarker of PARPi
sensitivity. Clinical trials with preliminary results show that BRCA2 and BRCA1, but
also ATM, additionally BRIP1, FANCA, CDK12 and PALB2 may affect clinical end points,
and may be potential candidates for genome guided patient selection in PARP inhibitor
treatment of prostate cancer.
